Key Updates and Expert Discussion from Myeloma Rounds
Recorded on: September 3, 2024
Recorded on: September 3, 2024
1.50 CME Credits for physicians available until: October 13, 2025
1.50 CPE Contact hour for pharmacists available until: October 13, 2025
1.50 CE Credit/Contact hours for nurses available until: October 13, 2025
1.50 CE Credit/Contact hours for nurse practitioners available until: November 30, 2025
Format: Non-interactive recorded webinar
Download: Program Slides
Target Audience
This activity is intended for hematologists-oncologists, medical oncologists, physician associates, nurse practitioners, nurses and pharmacists involved in the care of patients with myeloma.
Description
This webinar will feature highlights from Myeloma Rounds in Durham and Philadelphia that were held in the spring of 2024, as well as highlights of additional clinical updates after the Rounds. Discussion will cover the latest advancements in myeloma, including current and emerging therapies, clinical trials, optimal patient care strategies, disparities and challenges in diagnosis and treatment, and evidence-based treatment approaches. A review of educational resources for you, as well as resources that you can share with your patients will also be provided.
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the latest developments in myeloma, including current and emerging treatments
- Engage patients and caregivers in discussions on clinical trials, newly approved therapies and emerging therapies for myeloma, including combination therapies, CAR T-cell therapy and bispecific antibodies
- Identify disparities and challenges in diagnosis and treatment of myeloma
- Apply evidence-based treatment strategies for optimal patient care
- Access patient support resources
Faculty
Edward A. Stadtmauer, MD (Chair, Myeloma Rounds, Philadelphia)
Section Chief, Hematologic Malignancies
Roseman, Tarte, Harrow, and Shaffer Families’
President’s Distinguished Professor
University of Pennsylvania Abramson Cancer Center
Philadelphia, PA
Cindy Varga, MD (Chair, Myeloma Rounds, Durham)
Associate Professor
Atrium Health Levine Cancer Institute
Plasma Cell Dyscrasia Division
Department of Hematology and Oncology
Charlotte, NC
Continuing Education Information
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., and The Leukemia & Lymphoma Society. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Associate
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.50 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-24-076-H01-P
Type of Activity: Application
Registered Nursing Credit Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.50 continuing education contact hours through the California Board of Registered Nursing.
Nurse Practitioner Continuing Education
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.5 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 24106941. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
Providers
This activity is provided by The Leukemia & Lymphoma Society and Medical Learning Institute, Inc., in collaboration with the Association of Cancer Care Centers™ (ACCC).
Supporter Statement
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: ProfEducation@LLS.org.